Skip to main content
Article
Characterization of Clinical Benefits in Subjects Classified As ACR20 Non-Responders at Week 104 of Apremilast Treatment: Subanalysis of 3 Long-Term, Phase III Trials
Arthritis & Rheumatism (2017)
  • Philip J. Mease, University of Washington
  • Dafna D. Gladman, Toronto Western Hospital
  • Arthur Kavanaugh, University of California, San Diego
  • Priscila Nakasato
  • Benoit Guerette
  • Lichen Teng, Celgene
  • Peter Nash, University of Queensland
Publication Date
October 1, 2017
Citation Information
Philip J. Mease, Dafna D. Gladman, Arthur Kavanaugh, Priscila Nakasato, et al.. "Characterization of Clinical Benefits in Subjects Classified As ACR20 Non-Responders at Week 104 of Apremilast Treatment: Subanalysis of 3 Long-Term, Phase III Trials" Arthritis & Rheumatism Vol. 69 (2017)
Available at: http://works.bepress.com/philip-mease/31/